Shift of statin use towards the elderly in 1995-2005: A nation-wide register study in Finland

British Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2008, Pages 405-410

  Ruokoniemi, Päivi ^a,b   Helin Salmivaara, Arja ^a,c   Klaukka, Timo ^d   Neuvonen, Pertti J ^c   Huupponen, Risto ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b Clinical Pharmacology   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Incidence; Prevalence; Statins; Utilization

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; DRUG USE; FEMALE; FINLAND; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REGISTER; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; CORONARY DISEASE; DRUG UTILIZATION REVIEW; FEMALE; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; TIME FACTORS;

EID: 49549088373     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03258.x     Document Type: Article

References (28)

1. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998 317 : 1134 5.
2. Larsen J, Andersen M, Kragstrup J, Gram LF. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. Eur J Clin Pharmacol 2001 57 : 343 8.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 : 1301 7.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 335 : 1001 9.
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 57.
7. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000 108 : 496 9.
8. Martikainen J, Klaukka T, Reunanen A, Peura S, Wahlroos H. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 1996 49 : 1453 7.
9. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, Chinellato A. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 2007 63 : 197 203.
10. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J 2001 141 : 957 63.
11. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001 357 : 995 1001.
12. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997 53 : 185 9.
13. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000 49 : 463 71.
14. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol 2002 53 : 379 85.
15. Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske Johnsen S, Sorensen HT. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. Br J Clin Pharmacol 2001 52 : 307 11.
16. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005 60 : 543 51.
17. Nordic Medico Statistical Committee (Nomesco). Medicines Consumption in the Nordic Countries 1999-2003. Copenhagen, Denmark : Nomesco, 2004.
18. The National Agency for Medicines and the Social Insurance Institution. Finnish Statistics on Medicines 2005. Helsinki, Finland : National Agency for Medicines and the Social Insurance Institution, 2006.
19. The National Agency for Medicines. Classification of Medicines and the Defined Daily Doses 2005. Helsinki, Finland : National Agencies for Medicines, 2005.
20. The National Agency for Medicines. Classification of Medicines and the Defined Daily Doses 1995. Helsinki, Finland : National Agencies for Medicines, 1995.
21. Kattainen A, Salomaa V, Härkänen T, Jula A, Kaaja R, Kesäniemi YA, Kähönen M, Moilanen L, Nieminen MS, Aromaa A, Reunanen A. Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J 2006 27 : 296 301.
22. Pajunen P, Pääkkönen R, Juolevi A, Hämälä inen H, Keskimäki I, Laatikainen T, Moltchanov V, Niemi M, Rintanen H, Salomaa V. Trends in fatal and non-fatal coronary heart disease events in Finland during 1991-2001. Scand Cardiovasc J 2004 38 : 340 4.
23. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 360 : 1623 30.
24. Heart protection Study Collaborative Group. MRC/BHF heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 21.
25. Suomen Sisätautilääkärien yhdistyksen asettama työryhmä. Dyslipidemiat. Duodecim 2004 120 : 1794 1816 (in Finnish).
26. Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2000 health examination survey. Publications of the National Public Health Institute 2002 B S, Furu K, Karlstad Ø, Rønnig M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007 64 : 476 81.
27. Försäljningsstatistik. Statistics on medicinal product sales. Available at http://www2.apoteket.se/Apoteket/om/VadViGor/Forsalj/default.htm (last accessed 3 August 2007).
28. Danish Medicines Agency. Medicinal Product Statistics 2001-2005. Danish Medicines Agency, Denmark : Legemiddelstyrelsen, 2006.